|   | I. | U.S.      Provisional Patent Application No. 60/771,163, filed February 6, 2006,      entitled “Use of Phosphatases To Treat Glioblastomas” (HHS Ref. No.      E-123-2006/0-US-01); |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | II. | U.S.      Provisional Patent Application No. 60/797,201, filed May 2, 2006, entitled      “Use of Phosphatases To Treat Glioblastomas” (HHS Ref. No.      E-123-2006/1-US-01) |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | III. | U.S.      Patent Application Serial No. 11/703,401, filed February 6, 2007, entitled      “Use of Phosphatases To Treat Glioblastomas” (HHS Ref. No.      E-123-2006/0-US-03) |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | IV. | PCT      International Application No. PCT/US2007/003095, filed February 6, 2007      entitled “Use of Phosphatases To Treat Glioblastomas” (HHS Ref. No.      E-123-2006/0-PCT-02) |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | V. | U.S.      Provisional Patent Application No. 60/963,307, filed August 3, 2007      entitled “Use of Phosphatases To Treat Neuroblastomas and      Medulloblastomas” (HHS Ref. No.      E-123-2006/2-US-01) |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | VI. | U.S.      Provisional Patent Application No. 60/063,970, filed February 6, 2008      entitled “Use of  Phosphatases To Treat Neuroblastomas and      Medulloblastomas”. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | VII. | U.S.      Application in preparation corresponding to Cooper and Dunham Referene No.      4101/79251. |
|--------|------|-------------------------------------------------------------------------------------------------------|

----

|   | 1) | The      National Institutes of Health (“NIH”) or the Food and      Drug Administration (“FDA”), hereinafter      singly or collectively referred to as “PHS”, agencies of the      United States Public Health Service within the Department of Health and      Human Services (“HHS”);    and |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2) | The      person, corporation, or institution identified above or on the Signature      Page, having offices at the address indicated on the Signature Page,      hereinafter referred to as “Licensee”. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | PHS      PATENT LICENSE AGREEMENT – EXCLUSIVE |
|--------|-----------------------------------------------------|

| 1. | BACKGROUND |
|----|------------|

|   | 1.1 | In      the course of conducting biomedical research, PHS investigators made      inventions that may have commercial  applicability. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.2 | By      assignment of rights from PHS employees and other      inventors, HHS, on      behalf of the Government, owns intellectual property rights claimed in any      United States or foreign patent applications or patents corresponding to      the assigned inventions.  HHS also owns any      tangible embodiments of these inventions actually reduced to practice by      PHS. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.3 | The      Secretary of HHS      has delegated to PHS the authority to      enter into this Agreement      for the licensing of rights to these  inventions. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.4 | PHS desires to transfer      these inventions to the private sector through commercialization licenses      to facilitate the commercial development of products and processes for      public use and benefit. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.5 | Licensee      desires to acquire commercialization rights to certain of these inventions      in order to develop processes, methods, or marketable products for public      use and benefit. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | DEFINITIONS |
|----|-------------|

|   | 2.1 | “Benchmarks” mean the      performance milestones that are set forth in Appendix  D. |
|--------|-----|--------------------------------------------------------------------------------------------------|

|   | 2.2 | “Commercial Development      Plan” means the written commercialization plan attached as Appendix      E. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------|

|   | 2.3 | “First Commercial Sale”      means the initial transfer by or on behalf of Licensee or its      sublicensees of Licensed      Products or the initial practice of a Licensed Process by or      on behalf of Licensee or its      sublicensees in exchange for cash or some equivalent to which value can be      assigned for the purpose of determining Net    Sales. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.4 | “Government” means the      Government of the United States ofAmerica. |
|--------|-----|------------------------------------------------------------------------------------|

|   | 2.5 | “Licensed Fields of Use”      means the fields of use identified in Appendix  B. |
|--------|-----|----------------------------------------------------------------------------------------------|

|   | 2.6 | “Licensed Patent Rights”      shall mean: |
|--------|-----|-------------------------------------------------------|

|   | (a) | Patent      applications (including provisional patent applications and PCT patent      applications) or patents listed in Appendix A, all divisions and      continuations of these applications, all patents issuing from these      applications, divisions, and continuations, and any reissues,      reexaminations, and extensions of thesepatents; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | to      the extent that the following contain one or more claims directed to the      invention or inventions disclosed in2.6(a): |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | continuations      in part of 2.6(a); |
|--------|-----|---------------------------------------|

|   | (ii) | all      divisions and continuations of these continuations in  part; |
|--------|------|-----------------------------------------------------------------------|

----

|   | (iii) | all      patents issuing from these continuations in part, divisions, and      continuations; |
|--------|-------|-----------------------------------------------------------------------------------------------|

|   | (iv) | priority      patent application(s) of, and application(s) claiming priority of, 2.6(a);      and |
|--------|------|---------------------------------------------------------------------------------------------------|

|   | (v) | any      reissues, reexaminations, and extensions of these  patents; |
|--------|-----|----------------------------------------------------------------------|

|   | (c) | to      the extent that the following contain one or more claims directed to the      invention or inventions disclosed in 2.6(a): all counterpart foreign and      U.S. patent applications and patents to 2.6(a) and 2.6(b), including those      listed in Appendix A; and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | Licensed Patent Rights      shall not include 2.6(b) or 2.6(c) to the extent that they contain one or      more claims directed to new matter which is not the subject matter      disclosed in 2.6(a). |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.7 | “Licensed Processes”      means processes which, in the course of being practiced, would be within      the scope of one or more claims of the Licensed Patent Rights      that have not been held unpatentable, invalid or unenforceable by an      unappealed or unappealable judgment of a court of competent      jurisdiction. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.8 | “Licensed Products” means      tangible materials which, in the course of manufacture, use, sale, or      importation, would be within the scope of one or more claims of the Licensed Patent Rights      that have not been held unpatentable, invalid or unenforceable by an      unappealed or unappealable judgment of a court of competent      jurisdiction. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.9 | “Licensed Territory”      means the geographical area identified in Appendix  B. |
|--------|-----|----------------------------------------------------------------------------------------------|

|   | 2.10 | “Net      Sales” means the total gross receipts for sales of Licensed Products or      practice of Licensed      Processes by or on behalf of Licensee or its      sublicensees, and from leasing, renting, or otherwise making Licensed Products      available to others without sale or other dispositions, whether invoiced      or not, less returns and allowances, packing costs, insurance costs,      freight out, taxes or excise duties imposed on the transaction (if      separately invoiced), and wholesaler and cash discounts in amounts      customary in the trade to the extent actually granted.  No      deductions shall be made for commissions paid to individuals, whether they      are with independent sales agencies or regularly employed by Licensee, or      sublicensees, and on its payroll, or for the cost of      collections. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.11 | “Practical Application”      means to manufacture in the case of a composition or product, to practice      in the case of a process or method, or to operate in the case of a machine      or system; and in each case, under these conditions as to establish that      the invention is being utilized and that its benefits are to the extent      permitted by law or Government regulations      available to the public on reasonableterms. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.12 | “Research License” means      a nontransferable, nonexclusive license to make and to use Licensed Products or      Licensed Processes      as defined by the Licensed Patent Rights      for purposes of research and not for purposes of commercial manufacture or      distribution or in lieu ofpurchase. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.13 | "Affiliate(s)" means a      corporation or other business entity, which, directly or indirectly, is      controlled by, controls, or is under common control with Licensee.  For      this purpose, the term "control" shall mean ownership of more than fifty      percent (50%) of the voting stock or other ownership interest of the      corporation or other business entity, or the power to elect or appoint      more than fifty percent (50%) of the members of the governing body of the      corporation or other businessentity. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3. | GRANT OF      RIGHTS |
|----|----------------------|

|   | 3.1 | PHS hereby grants and      Licensee accepts,      subject to the terms and conditions of this Agreement, an exclusive      license under the Licensed Patent Rights      in the Licensed      Territory to make and have made, to use and have used, to sell and      have sold, to offer to sell, and to import any Licensed Products in the      Licensed Fields of Use and to practice and have practiced any Licensed Processes in      the Licensed Fields of      Use. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3.2 | This      Agreement confers      no license or rights by implication, estoppel, or otherwise under any      patent applications or patents of PHS other than the Licensed Patent Rights      regardless of whether these patents are dominant or subordinate to the      Licensed Patent      Rights. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4. | SUBLICENSING |
|----|--------------|

|   | 4.1 | Upon      written approval, which shall include prior review of any sublicense      agreement by PHS      and which shall not be unreasonably withheld, Licensee may enter into      sublicensing agreements under the Licensed Patent      Rights. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.2 | Licensee agrees that any      sublicenses granted by it shall provide that the obligations to PHS of Paragraphs 5.1      5.4, 8.1, 10.1, 10.2, 12.5, and 13.8-13.10 of this Agreement shall be      binding upon the sublicensee as if it were a party to this Agreement.  Licensee further agrees      to attach copies of these Paragraphs to all sublicense      agreements. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.3 | Any      sublicenses granted by Licensee shall provide      for the termination of the sublicense, or the conversion to a license      directly between the sublicensees and PHS, at the option of      the sublicensee, upon termination of this Agreement under Article      13.  This conversion is subject to PHS approval which will      not be unreasonably withheld and contingent upon acceptance by the      sublicensee of the remaining provisions of this Agreement. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.4 | Licensee agrees to      forward to PHS a      complete copy of each fully executed sublicense agreement postmarked      within thirty (30) days of the execution of the agreement.  To      the extent permitted by law, PHS agrees to maintain      each sublicense agreement inconfidence. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5. | STATUTORY AND PHS      REQUIREMENTS AND RESERVED GOVERNMENT  RIGHTS |
|----|---------------------------------------------------------------------|

|   | 5.1                (a) | PHS reserves on behalf      of the Government      an irrevocable, nonexclusive, nontransferable, royalty free license for      the practice of all inventions licensed under the Licensed Patent Rights      throughout the world by or on behalf of the Government and on behalf      of any foreign government or international organization pursuant to any      existing or future treaty or agreement to which the Government is a      signatory.  Prior to the First Commercial Sale,      Licensee agrees to      provide PHS with      reasonable quantities of Licensed Products or      materials made through the Licensed Processes for      PHS research use;      and |
|--------|--------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (b) | In      the event that the Licensed Patent Rights      are Subject Inventions made under a Cooperative Research and      Development Agreement (“CRADA”), Licensee grants to the      Government,      pursuant to 15 U.S.C. §3710a(b)(1)(A), a nonexclusive, nontransferable,      irrevocable, paid up license to practice Licensed Patent Rights      or have Licensed Patent      Rights practiced throughout the world by or on behalf of the Government.  In      the exercise of this license, the Government shall not      publicly disclose trade secrets or commercial or financial information      that is privileged or confidential within the meaning of 5 U.S.C.      §552(b)(4) or which would be considered as such if it had been obtained      from a non Federal party.  Prior to the First Commercial Sale,      Licensee agrees to      provide PHS      reasonable quantities of Licensed Products or      materials made through the Licensed Processes for      PHS research      use. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.2 | Licensee agrees that      products used or sold in the United States embodying Licensed Products or      produced through use of Licensed Processes shall      be manufactured substantially in the United States, unless a written      waiver is obtained in advance from PHS. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.3 | Licensee acknowledges      that PHS may enter      into future CRADAs      under the Federal Technology Transfer Act of 1986 that relate to the      subject matter of this Agreement.  Licensee agrees not to      unreasonably deny requests for a Research License from future      collaborators with PHS when acquiring these      rights is necessary in order to make a CRADA project      feasible.  Licensee may request an      opportunity to join as a party to the proposed CRADA. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.4 | (a) | In      addition to the reserved license of Paragraph 5.1, PHS reserves the right      to grant Research      Licenses directly or to require Licensee to grant Research Licenses on      reasonable terms.  The purpose of these Research Licenses is to      encourage basic research, whether conducted at an academic or corporate      facility.  In order to safeguard the Licensed Patent Rights,      however, PHS shall      consult with Licensee before granting      to commercial entities a Research License or providing to them research      samples of materials made through the Licensed Processes;      and |
|--------|-----|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | In      exceptional circumstances, and in the event that Licensed Patent Rights      are Subject Inventions made under a CRADA, the Government, pursuant to      15 U.S.C. §3710a(b)(1)(B), retains the right to require the Licensee to grant to a      responsible applicant a nonexclusive, partially exclusive, or exclusive      sublicense to use the Licensed Patent Rights      in the Licensed Field of      Use on terms that are reasonable under the circumstances, or if      Licensee fails to      grant this license, the Government retains the      right to grant the license itself.  The exercise of these rights      by the Government      shall only be in exceptional circumstances and only if the Government      determines: |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | the      action is necessary to meet health or safety needs that are not reasonably      satisfied by Licensee; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------|

|   | (ii) | the      action is necessary to meet requirements for public use specified by      Federal regulations, and these requirements are not reasonably satisfied      by the Licensee;      or |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | the      Licensee has      failed to comply with an agreement containing provisions described in 15      U.S.C. §3710a(c)(4)(B); and |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | The      determination made by the Government under this      Paragraph 5.4 is subject to administrative appeal and judicial review      under 35 U.S.C. §203(2). |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6. | ROYALTIES AND      REIMBURSEMENT |
|----|----------------------------------|

|   | 6.1 | Licensee agrees to pay      PHS a      noncreditable, nonrefundable license issue royalty as set forth in      Appendix C. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------|

----

|   | 6.2 | Licensee agrees to pay      PHS a      nonrefundable minimum annual royalty as set forth in Appendix      C. |
|--------|-----|--------------------------------------------------------------------------------------------------------------|

|   | 6.3 | Licensee agrees to pay      PHS earned      royalties as set forth in AppendixC. |
|--------|-----|----------------------------------------------------------------------------------|

|   | 6.4 | Licensee agrees to pay      PHS benchmark      royalties as set forth in AppendixC. |
|--------|-----|-------------------------------------------------------------------------------------|

|   | 6.5 | Licensee agrees to pay      PHS sublicensing      royalties as set forth in AppendixC. |
|--------|-----|----------------------------------------------------------------------------------------|

|   | 6.6 | A      patent or patent application licensed under this Agreement shall cease to      fall within the Licensed      Patent Rights for the purpose of computing earned royalty payments      in any given country on the earliest of the dates  that: |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | the      application has been abandoned and not  continued; |
|--------|-----|-------------------------------------------------------------|

|   | (b) | the      patent expires or irrevocably lapses,or |
|--------|-----|--------------------------------------------------|

|   | (c) | the      claim has been held to be invalid or unenforceable by an unappealed or      unappealable decision of a court of competent jurisdiction or      administrative agency. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.7 | No      multiple royalties shall be payable because any Licensed Products or      Licensed Processes      are covered by more than one of the Licensed Patent      Rights. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.8 | On      sales of Licensed      Products by Licensee to sublicensees      or on sales made in other than an arms length transaction, the value of      the Net Sales attributed under this Article 6 to this transaction shall be      that which would have been received in an arms length transaction, based      on sales of like quantity and quality products on or about the time of      this transaction. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.9 | PHS has not incurred any      expenses associated with the preparation, filing, prosecution, and      maintenance of the patent applications and patents included within the      Licensed Patent      Rights prior to the effective date of this    Agreement. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.10 | With      regard to expenses associated with the preparation, filing, prosecution,      and maintenance of all patent applications and patents included within the      Licensed Patent      Rights and incurred by PHS on or after the      effective date of this Agreement, PHS, at its sole option,      may require Licensee: |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | to      pay PHS on an      annual basis, within sixty (60) days of PHS’ submission of a      statement and request for payment, a royalty amount equivalent to these      patent expenses incurred during the previous calendar    year(s); |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | to      pay these expenses directly to the law firm employed by PHS to handle these      functions.  However, in this event, PHS and not Licensee shall be the      client of the law firm; or |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | in      limited circumstances, Licensee may be given      the right to assume responsibility for the preparation, filing,      prosecution, or maintenance of any patent application or patent included      with the Licensed Patent      Rights.  In that event, Licensee shall directly      pay the attorneys or agents engaged to prepare, file, prosecute, or      maintain these patent applications or patents and shall provide PHS with copies of each      invoice associated with these services as well as documentation that these      invoices have been paid. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 6.11 | PHS agrees, upon written      request, to provide Licensee with summaries      of patent prosecution invoices for which PHS has requested      payment from the Licensee under      Paragraphs 6.9 and 6.10.  Licensee agrees that all      information provided by PHS related to patent      prosecution costs shall be treated as confidential commercial information      and shall not be released to a third party except as required by law or a      court of competent jurisdiction. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.12 | Licensee may elect to      surrender its rights in any country of the Licensed Territory under      any of the Licensed      Patent Rights upon ninety (90) days written notice to PHS and owe no payment      obligation under Paragraph 6.10 for patent-related expenses incurred in      that country after ninety (90) days of the effective date of the written      notice. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7. | PATENT FILING,      PROSECUTION, AND MAINTENANCE |
|----|--------------------------------------------------|

|   | 7.1 | Licensee shall file,      prosecute, and maintain patent application(s) relating to the Licensed Patent Rights      and shall promptly provide to PHS all serial numbers      and filing dates, together with copies of all these applications,      including copies of all Patent Office actions, responses, and all other      Patent Office communications.  In addition, Licensee shall file with      Patent Offices a Power of Attorney that names both Licensee and PHS or names inventors      of the Licensed Patent      Rights who are obligated to assign to Licensee or PHS.  This      Power of Attorney shall be filed with every Patent Office involved in      prosecuting all patent applications pertaining to Licensed Patent      Rights.  Licensee shall consult      with PHS, when so      requested, prior to communicating with any Patent Office with respect to      the Licensed Patent      Rights.  PHS shall timely provide      to Licensee or its      attorneys any formal document necessary to file, prosecute, and maintain      patents and patent applications relating to the Licensed Patent      Rights. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 7.2 | Licensee shall make an      election with respect to foreign filing, upon consultation with PHS, including which      countries foreign filing shall be done prior to the election, within eight      (8) months of any United States filing.  If any foreign patent      applications are filed, Licensee shall promptly      provide to PHS all      serial numbers and filing dates.  Licensee also shall      provide PHS copies      of foreign patent applications and Patent Office actions.  Licensee shall consult      with PHS, when so      requested, prior to communication with any Patent Office with respect to      the Licensed Patent      Rights. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 7.3 | Licensee shall promptly      record available Assignments of domestic Licensed Patent Rights      in the United States Patent and Trademark Office and shall promptly      provide PHS with      the original of each recorded Assignment with respect to PHS. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 7.4 | Notwithstanding      any other provision of this Agreement, Licensee shall not      abandon the prosecution of any patent application, including provisional      patent applications (except for purposes of filing continuation      application(s)) or the maintenance of any patent contemplated by this      Agreement, without prior written notice to PHS.  Upon      receiving the written notice, PHS may, at its sole      option, take over the prosecution of any patent application, or the      maintenance of any patent. Licensee agrees to      furnish written notice to PHS as soon as possible      after Licensee’s      decision to abandon prosecution, and Licensee will not      abandon prosecution within thirty (30) days of a prosecution deadline.      Licensee shall      promptly provide PHS with copies of all      issued patents under thisAgreement. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 7.5 | Licensee shall promptly      provide PHS with      copies of all issued patents under this  Agreement. |
|--------|-----|--------------------------------------------------------------------------------------------------------|

|   | 7.6 | In      the event that Licensee anticipates the      possibility of any extraordinary expenditures arising from the      preparation, filing, prosecution, licensing, or defense of any patent      application or patent contemplated by this Agreement, including, without      limitation, interferences, reexaminations, reissues and oppositions, Licensee shall provide      PHS with all      relevant information. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 8. | RECORD      KEEPING |
|----|---------------------|

|   | 8.1 | Licensee agrees to keep      accurate and correct records of Licensed Products made,      used, sold, or imported and Licensed Processes      practiced under this Agreement appropriate to determine the amount of      royalties due PHS.  These      records shall be retained for at least five (5) years following a given      reporting period and shall be available during normal business hours for      inspection, at the expense of PHS, by an accountant or      other designated auditor selected by PHS for the sole purpose      of verifying reports and royalty payments hereunder.  The      accountant or auditor shall only disclose to PHS information relating      to the accuracy of reports and royalty payments made under this      Agreement.  If an inspection shows an underreporting or      underpayment in excess of five percent (5%) for any twelve (12) month      period, then Licensee shall reimburse      PHS for the cost      of the inspection at the time Licensee pays the      unreported royalties, including any additional royalties as required by      Paragraph 9.8.  All royalty payments required under this      Paragraph shall be due within thirty (30) days of the date PHS provides Licensee notice of the      payment due. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 8.2 | Licensee agrees to have      an audit of sales and royalties conducted by an independent auditor at      least every two (2) years if annual sales of the Licensed Products or      Licensed Processes      are over ten (10) million dollars.  The audit shall address, at      a minimum, the amount of gross sales by or on behalf of Licensee during the      audit period, terms of the license as to percentage or fixed royalty to be      remitted to the Government, the amount      of royalties owed to the Government under this      Agreement, and whether the royalties owed have been paid to the Government and is      reflected in the records of the Licensee.  The      audit shall also indicate the PHS license number,      product, and the time period being audited.  A report certified      by the auditor shall be submitted promptly by the auditor directly to      PHS on      completion.  Licensee shall pay for      the entire cost of the audit. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9. | REPORTS ON PROGRESS,      BENCHMARKS, SALES, ANDPAYMENTS |
|----|----------------------------------------------------------|

|   | 9.1 | Prior      to signing this Agreement, Licensee has provided      PHS with the Commercial Development Plan      in Appendix E, under which Licensee intends to      bring the subject matter of the Licensed Patent Rights      to the point of Practical      Application.  This Commercial Development Plan      is hereby incorporated by reference into this Agreement.  Based      on this plan, performance Benchmarks are      determined as specified in AppendixD. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.2 | Licensee shall provide      written annual reports on its product development progress or efforts to      commercialize under the Commercial Development Plan      for each of the Licensed Fields of Use      within sixty (60) days after December 31 of each calendar      year.  These progress reports shall include, but not be limited      to: progress on research and development, status of applications for      regulatory approvals, manufacturing, sublicensing, marketing, importing,      and sales during the preceding calendar year, as well as, plans for the      present calendar year.  PHS also encourages      these reports to include information on any of Licensee's public      service activities that relate to the Licensed Patent      Rights.  If reported progress differs from that projected      in the Commercial      Development Plan and Benchmarks, Licensee shall explain      the reasons for these differences.  In the annual report, Licensee may propose      amendments to the Commercial Development      Plan, acceptance of which by PHS may not be denied      unreasonably.  Licensee agrees to      provide any additional information reasonably required by PHS to evaluate Licensee's performance      under this Agreement.  Licensee may amend the      Benchmarks at any      time upon written approval by PHS. PHS shall not      unreasonably withhold approval of any request of Licensee to extend the      time periods of this schedule if the request is supported by a reasonable      showing by Licensee of diligence in      its performance under the Commercial Development      Plan and toward bringing the Licensed Products to the      point of Practical      Application as defined in 37 CFR §404.3(d).  Licensee shall amend the      Commercial Development      Plan and Benchmarks at the      request of PHS to      address any Licensed Fields of Use not specifically addressed in the plan      originally submitted. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 9.3 | Licensee shall report to      PHS the dates for      achieving Benchmarks specified in      Appendix D and the First      Commercial Sale in each country in the Licensed Territory      within thirty (30) days of suchoccurrences. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.4 | Licensee shall submit to      PHS, within sixty      (60) days after each calendar half year ending June 30 and December 31, a      royalty report, as described in the example in Appendix F, setting forth      for the preceding half year period the amount of the Licensed Products sold      or Licensed      Processes practiced by or on behalf of Licensee in each country      within the Licensed      Territory, the Net      Sales, and the amount of royalty accordingly due.  With      each royalty report, Licensee shall submit      payment of earned royalties due.  If no earned royalties are due      to PHS for any      reporting period, the written report shall so state.  The      royalty report shall be certified as correct by an authorized officer of      Licensee and shall      include a detailed listing of all deductions made under Paragraph 2.10 to      determine Net      Sales made under Article 6 to determine royalties    due. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.5 | Licensee agrees to      forward semi annually to PHS a copy of these      reports received by Licensee from its      sublicensees during the preceding half year period as shall be pertinent      to a royalty accounting to PHS by Licensee for activities      under the sublicense. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.6 | Royalties      due under Article 6 shall be paid in U.S. dollars and payment options are      listed in Appendix G.  For conversion of foreign currency to      U.S. dollars, the conversion rate shall be the New York foreign exchange      rate quoted in The Wall      Street Journal on the day that the payment is due.  Any      loss of exchange, value, taxes, or other expenses incurred in the transfer      or conversion to U.S. dollars shall be paid entirely by Licensee.  The      royalty report required by Paragraph 9.4 shall be mailed to PHS at its address for      Agreement Notices indicated on the Signature  Page. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.7 | Licensee shall be solely      responsible for determining if any tax on royalty income is owed outside      the United States and shall pay the tax and be responsible for all filings      with appropriate agencies of foreign  governments. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.8 | Additional      royalties may be assessed by PHS on any payment that      is more than ninety (90) days overdue at the rate of one percent (1%) per      month.  This one percent (1%) per month rate may be applied      retroactively from the original due date until the date of receipt by      PHS of the overdue      payment and additional royalties.  The payment of any additional      royalties shall not prevent PHS from exercising any      other rights it may have as a consequence of the lateness of any      payment. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.9 | All      plans and reports required by this Article 9 and marked “confidential” by      Licensee shall, to      the extent permitted by law, be treated by PHS as commercial and      financial information obtained from a person and as privileged and      confidential, and any proposed disclosure of these records by the PHS under the Freedom of      Information Act (FOIA), 5 U.S.C. §552 shall be subject to the      predisclosure notification requirements of 45 CFR  §5.65(d). |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10. | PERFORMANCE |
|-----|-------------|

|   | 10.1 | Licensee shall use its      reasonable commercial efforts to bring the Licensed Products and      Licensed Processes      to Practical      Application.  “Reasonable commercial efforts” for the      purposes of this provision shall include adherence to the Commercial Development      Plan in Appendix E and performance of the Benchmarks in Appendix      D.  The efforts of a sublicensee shall be considered the efforts      of Licensee. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.2 | Upon      the First Commercial      Sale, until the expiration or termination of this Agreement, Licensee shall use its      reasonable commercial efforts to make Licensed Products and      Licensed Processes      reasonably accessible to the United States  public. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.3 | Licensee agrees, after      its First Commercial      Sale, to make reasonable quantities of Licensed Products or      materials produced through the use of Licensed Processes      available on a compassionate use basis to patients, either through the      patient’s physician(s) or the medical center treating the      patient. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.4 | Licensee agrees, after      its First Commercial      Sale and as part of its marketing and product promotion, to develop      educational materials (e.g., brochures, website, etc.) directed to      patients and physicians detailing the Licensed Products or      medical aspects of the prophylactic and therapeutic uses of the Licensed      Products. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.5 | Licensee agrees to      supply, to the Mailing Address for Agreement Notices indicated on the      Signature Page, the Office of Technology Transfer, NIH with inert samples      of the Licensed      Products or Licensed Processes or      their packaging for educational and display purposes  only. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11. | INFRINGEMENT AND      PATENT ENFORCEMENT |
|-----|------------------------------------------|

|   | 11.1 | PHS and Licensee agree to notify      each other promptly of each infringement or possible infringement of the      Licensed Patent      Rights, as well as, any facts which may affect the validity, scope,      or enforceability of the Licensed Patent Rights      of which either party becomesaware. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11.2 | Pursuant      to this Agreement and the provisions of Chapter 29 of Title 35, United      States Code, Licensee      may: |
|--------|------|---------------------------------------------------------------------------------------------------------------------------|

|   | (a) | bring      suit in its own name, at its own expense, and on its own behalf for      infringement of presumably valid claims in the Licensed Patent      Rights; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | in      any suit, enjoin infringement and collect for its use, damages, profits,      and awards of whatever nature recoverable for the infringement;      or |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | settle      any claim or suit for infringement of the Licensed Patent Rights      provided, however, that PHS and appropriate      Government      authorities shall have the first right to take such actions;      and |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (d) | If      Licensee desires      to initiate a suit for patent infringement, Licensee shall notify      PHS in      writing.  If PHS does not notify      Licensee of its      intent to pursue legal action within ninety (90) days, Licensee shall be free      to initiate suit.  PHS shall have a      continuing right to intervene in the suit.  Licensee shall take no      action to compel the Government either to      initiate or to join in any suit for patent infringement.  Licensee may request the      Government to      initiate or join in any suit if necessary to avoid dismissal of the suit.      Should the Government be made a      party to any suit, Licensee shall reimburse      the Government for      any costs, expenses, or fees which the Government incurs as a      result of the motion or other action, including all costs incurred by the      Government in      opposing the motion or other action.  In all cases, Licensee agrees to keep      PHS reasonably      apprised of the status and progress of any litigation.  Before      Licensee commences      an infringement action, Licensee shall notify      PHS and give      careful consideration to the views of PHS and to any potential      effects of the litigation on the public health in deciding whether to      bring suit. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11.3 | In      the event that a declaratory judgment action alleging invalidity or non      infringement of any of the Licensed Patent Rights      shall be brought against Licensee or raised by      way of counterclaim or affirmative defense in an infringement suit brought      by Licensee under      Paragraph 11.2, pursuant to this Agreement and the provisions of Chapter      29 of Title 35, United States Code or other statutes, Licensee      may: |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | defend      the suit in its own name, at its own expense, and on its own behalf for      presumably valid claims in the Licensed Patent      Rights; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | in      any suit, ultimately to enjoin infringement and to collect for its use,      damages, profits, and awards of whatever nature recoverable for the      infringement; and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | settle      any claim or suit for declaratory judgment involving the Licensed Patent      Rights-provided, however, that PHS and appropriate      Government      authorities shall have the first right to take these actions and shall      have a continuing right to intervene in the suit;  and |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | If      PHS does not      notify Licensee of      its intent to respond to the legal action within a reasonable time, Licensee shall be free      to do so.  Licensee shall take no      action to compel the Government either to      initiate or to join in any declaratory judgment action.  Licensee may request the      Government to      initiate or to join any suit if necessary to avoid dismissal of the      suit.  Should the Government be made a      party to any suit by motion or any other action of Licensee, Licensee shall reimburse      the Government for      any costs, expenses, or fees, which the Government incurs as a      result of the motion or other action.  If Licensee elects not to      defend against the declaratory judgment action, PHS, at its option, may      do so at its own expense.  In all cases, Licensee agrees to keep      PHS reasonably      apprised of the status and progress of any litigation.  Before      Licensee commences      an infringement action, Licensee shall notify      PHS and give      careful consideration to the views of PHS and to any potential      effects of the litigation on the public health in deciding whether to      bring suit. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11.4 | In      any action under Paragraphs 11.2 or 11.3 the expenses including costs,      fees, attorney fees, and disbursements, shall be paid by Licensee.  The      value of any recovery made by Licensee through court      judgment or settlement shall be treated as Net Sales and subject to      earned royalties. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11.5 | PHS shall cooperate      fully with Licensee in connection      with any action under Paragraphs 11.2 or 11.3.  PHS agrees promptly to      provide access to all necessary documents and to render reasonable      assistance in response to a request by Licensee. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12. | NEGATION OF WARRANTIES      AND INDEMNIFICATION |
|-----|-------------------------------------------------|

|   | 12.1 | PHS offers no warranties      other than those specified in Article1. |
|--------|------|-----------------------------------------------------------------------|

----

|   | 12.2 | PHS does not warrant the      validity of the Licensed      Patent Rights and makes no representations whatsoever with regard      to the scope of the Licensed Patent Rights,      or that the Licensed      Patent Rights may be exploited without infringing other patents or      other intellectual property rights of third  parties. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 12.3 | PHS MAKES NO WARRANTIES,      EXPRESSED OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR      PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED PATENT      RIGHTS OR TANGIBLE MATERIALS RELATEDTHERETO. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 12.4 | PHS does not represent      that it shall commence legal actions against third parties infringing the      Licensed Patent      Rights. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------|

|   | 12.5 | Licensee shall indemnify      and hold PHS, its      employees, students, fellows, agents, and consultants harmless from and      against all liability, demands, damages, expenses, and losses, including      but not limited to death, personal injury, illness, or property damage in      connection with or arising out of: |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | the      use by or on behalf of Licensee, its      sublicensees, directors, employees, or third parties of any Licensed Patent Rights;      or |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | the      design, manufacture, distribution, or use of any Licensed Products, Licensed Processes or      materials by Licensee, or other      products or processes developed in connection with or arising out of the      Licensed Patent      Rights. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 12.6 | Licensee agrees to      maintain a liability insurance program consistent with sound business      practice. |
|--------|------|--------------------------------------------------------------------------------------------------------------|

| 13. | TERM, TERMINATION, AND      MODIFICATION OF RIGHTS |
|-----|----------------------------------------------------|

|   | 13.1 | This      Agreement is effective when signed by all parties, unless the provisions      of Paragraph 14.16 are not fulfilled, and shall extend to the expiration      of the last to expire of the Licensed Patent Rights      unless sooner terminated as provided in this Article  13. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 13.2 | In      the event that Licensee is in default      in the performance of any material obligations under this Agreement,      including but not limited to the obligations listed in Paragraph 13.5, and      if the default has not been remedied within ninety (90) days after the      date of notice in writing of the default, PHS may terminate this      Agreement by written notice and pursue outstanding royalties owed through      procedures provided by the Federal Debt Collection  Act. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 13.3 | In      the event that Licensee becomes      insolvent, files a petition in bankruptcy, has such a petition filed      against it, determines to file a petition in bankruptcy, or receives      notice of a third party's intention to file an involuntary petition in      bankruptcy, Licensee shall      immediately notify PHS in      writing.  Furthermore, PHS shall have the right      to terminate this Agreement immediately upon Licensee's receipt of      written notice. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 13.4 | Licensee shall have a      unilateral right to terminate this Agreement or any licenses in any      country or territory by giving PHS sixty (60) days      written notice to that effect. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 13.5 | PHS shall specifically      have the right to terminate or modify, at its option, this Agreement,      subject to paragraph 13.2, if PHS determines that the      Licensee: |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (a) | is      not executing the Commercial Development      Plan submitted with its request for a license and the Licensee cannot      otherwise demonstrate to PHS’ reasonable      satisfaction that the Licensee has taken, or      can be expected to take within a reasonable time, effective steps to      achieve Practical      Application of the Licensed Products or      Licensed      Processes; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | has      not achieved the Benchmarks as may be      modified under Paragraph 9.2; |
|--------|-----|-----------------------------------------------------------------------------------|

|   | (c) | has      willfully made a false statement of, or willfully omitted a material fact      in the license application or in any report required by the license      Agreement; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | has      committed a material breach of a covenant or agreement contained in this      Agreement; |
|--------|-----|---------------------------------------------------------------------------------------------------|

|   | (e) | is      not keeping Licensed      Products or Licensed Processes      reasonably available to the public after commercial use      commences; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------|

|   | (f) | cannot      reasonably satisfy unmet health and safety needs;  or |
|--------|-----|-------------------------------------------------------------------|

|   | (g) | cannot      reasonably justify a failure to comply with the domestic production      requirement of Paragraph 5.2 unlesswaived. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------|

|   | 13.6 | In      making the determination referenced in Paragraph 13.5, PHS shall take into      account the normal course of such commercial development programs      conducted with sound and reasonable business practices and judgment and      the annual reports submitted by Licensee under Paragraph      9.2.  Prior to invoking termination or modification of this      Agreement under Paragraph 13.5, PHS shall give written      notice to Licensee      providing Licensee      specific notice of, and a ninety (90) day opportunity to respond to, PHS’ concerns as to the      items referenced in 13.5(a)-13.5(g).  If Licensee fails to      alleviate PHS’      concerns as to the items referenced in 13.5(a)-13.5(g) or fails to      initiate corrective action to PHS’ reasonable      satisfaction, PHS      may terminate this Agreement. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 13.7 | When      the public health and safety so require, and after written notice to Licensee providing Licensee a sixty (60)      day opportunity to respond, PHS shall have the right      to require Licensee to grant      sublicenses to responsible applicants, on reasonable terms, in any      Licensed Fields of Use under the Licensed Patent Rights,      unless Licensee      can reasonably demonstrate that the granting of the sublicense would not      materially increase the availability to the public of the subject matter      of the Licensed Patent      Rights.  PHS shall not require      the granting of a sublicense unless the responsible applicant has first      negotiated in good faith with Licensee. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 13.8 | PHS reserves the right      according to 35 U.S.C. §209(d)(3) to terminate or modify this Agreement if      it is determined that this action is necessary to meet the requirements      for public use specified by federal regulations issued after the date of      the license and these requirements are not reasonably satisfied by Licensee. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 13.9 | Within      thirty (30) days of receipt of written notice of PHS' unilateral decision      to modify or terminate this Agreement, Licensee may, consistent      with the provisions of 37 CFR §404.11, appeal the decision by written      submission to the designated PHS      official.  The decision of the designated PHS official shall be      the final agency decision.  Licensee may thereafter      exercise any and all administrative or judicial remedies that may be      available. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | 13.10 | Within      ninety (90) days of expiration or termination of this Agreement under this      Article 13, a final report shall be submitted by Licensee.  Any      royalty payments, including those incurred but not yet paid (such as the      full minimum annual royalty), and those related to patent expense, due to      PHS shall become      immediately due and payable upon termination or expiration.  If      terminated under this Article 13, sublicensees may elect to convert their      sublicenses to direct licenses with PHS pursuant to      Paragraph 4.3.  Unless otherwise specifically provided for under      this Agreement, upon termination or expiration of this Agreement, Licensee shall return      all Licensed      Products or other materials included within the Licensed Patent Rights      to PHS or provide      PHS with      certification of the destructionthereof. |
|--|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14. | GENERAL      PROVISIONS |
|-----|-------------------------|

|   | 14.1 | Neither      party may waive or release any of its rights or interests in this      Agreement except in writing.  The failure of the Government to assert a      right hereunder or to insist upon compliance with any term or condition of      this Agreement shall not constitute a waiver of that right by the Government or excuse a      similar subsequent failure to perform any of these terms or conditions by      Licensee. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.2 | This      Agreement constitutes the entire agreement between the parties relating to      the subject matter of the Licensed Patent Rights,      Licensed Products      and Licensed      Processes, and all prior negotiations, representations, agreements,      and understandings are merged into, extinguished by, and completely      expressed by this Agreement. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.3 | The      provisions of this Agreement are severable, and in the event that any      provision of this Agreement shall be determined to be invalid or      unenforceable under any controlling body of law, this determination shall      not in any way affect the validity or enforceability of the remaining      provisions of this Agreement. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.4 | If      either party desires a modification to this Agreement, the parties shall,      upon reasonable notice of the proposed modification by the party desiring      the change, confer in good faith to determine the desirability of the      modification.  No modification shall be effective until a      written amendment is signed by the signatories to this Agreement or their      designees. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.5 | The      construction, validity, performance, and effect of this Agreement shall be      governed by Federal law as applied by the Federal courts in the District      of Columbia. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.6 | All      Agreement notices required or permitted by this Agreement shall be given      by prepaid, first class, registered or certified mail or by an      express/overnight delivery service provided by a commercial carrier,      properly addressed to the other party at the address designated on the      following Signature Page, or to another address as may be designated in      writing by the other party. Agreement notices shall be considered timely      if the notices are received on or before the established deadline date or      sent on or before the deadline date as verifiable by U.S. Postal Service      postmark or dated receipt from a commercial carrier.  Parties      should request a legibly dated U.S. Postal Service postmark or obtain a      dated receipt from a commercial carrier or the U.S. Postal      Service.  Private metered postmarks shall not be acceptable as      proof of timely mailing. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.7 | This      Agreement may not be assigned without prior written permission from PHS except to an      Affiliate, which permission shall not be unreasonably      withheld.  Licensee shall provide      PHS a minimum of      sixty (60) days to grant the written permission.  In the event      that no response from PHS during the sixty      (60) day period is received, Licensee shall consider      the permission granted.  Licensee shall pay PHS, as an additional      royalty, one percent (1%) of the fair market value of any consideration      received for any assignment of this Agreement within thirty (30) days of      the assignment. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 14.8 | Licensee agrees in its      use of any PHS      supplied materials to comply with all applicable statutes, regulations,      and guidelines, including PHS and HHS regulations and      guidelines.  Licensee agrees not to      use the materials for research involving human subjects or clinical trials      in the United States without complying with 21 CFR Part 50 and 45 CFR Part      46.  Licensee agrees not to      use the materials for research involving human subjects or clinical trials      outside of the United States without notifying PHS, in writing, of the      research or trials and complying with the applicable regulations of the      appropriate national control authorities.  Written notification      to PHS of research      involving human subjects or clinical trials outside of the United States      shall be given no later than sixty (60) days prior to commencement of the      research or trials. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.9 | Licensee acknowledges      that it is subject to and agrees to abide by the United States laws and      regulations (including the Export Administration Act of 1979 and Arms      Export Control Act) controlling the export of technical data, computer      software, laboratory prototypes, biological material, and other      commodities.  The transfer of these items may require a license      from the appropriate agency of the U.S. Government or written      assurances by Licensee that it shall      not export these items to certain foreign countries without prior approval      of this agency.  PHS neither represents      that a license is or is not required or that, if required, it shall be      issued. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 14.10 | Licensee agrees to mark      the Licensed      Products or their packaging sold in the United States with all      applicable U.S. patent numbers and similarly to indicate “Patent Pending”      status.  All Licensed Products      manufactured in, shipped to, or sold in other countries shall be marked in      a manner to preserve PHS patent rights in      those countries. |
|--|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 14.11 | By      entering into this Agreement, PHS does not directly or      indirectly endorse any product or service provided, or to be provided, by      Licensee whether      directly or indirectly related to this Agreement.  Licensee shall not state      or imply that this Agreement is an endorsement by the Government, PHS, any other Government      organizational unit, or any Government      employee.  Additionally, Licensee shall not use      the names of NIH,      FDA, PHS, or HHS or the Government or their      employees in any advertising, promotional, or sales literature without the      prior written approval of PHS. |
|--|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 14.12 | The      parties agree to attempt to settle amicably any controversy or claim      arising under this Agreement or a breach of this Agreement, except for      appeals of modifications or termination decisions provided for in Article      13.  Licensee agrees first to      appeal any unsettled claims or controversies to the designated PHS official, or      designee, whose decision shall be considered the final agency      decision.  Thereafter, Licensee may exercise      any administrative or judicial remedies that may be    available. |
|--|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 14.13 | Nothing      relating to the grant of a license, nor the grant itself, shall be      construed to confer upon any person any immunity from or defenses under      the antitrust laws or from a charge of patent misuse, and the acquisition      and use of rights pursuant to 37 CFR Part 404 shall not be immunized from      the operation of state or Federal law by reason of the source of the      grant. |
|--|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 14.14 | Any      formal recordation of this Agreement required by the laws of any Licensed Territory as a      prerequisite to enforceability of the Agreement in the courts of any      foreign jurisdiction or for other reasons will be carried out by Licensee at its expense,      and appropriately verified proof of recordation will be promptly furnished      to PHS. |
|--|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 14.15 | Paragraphs      4.3, 8.1, 9.5-9.7, 12.1-12.5, 13.9, 13.10, and 14.13 of this Agreement      shall survive termination of thisAgreement. |
|--|-------|-----------------------------------------------------------------------------------------------------------------------------------------|

----

|  | 14.16 | The      terms and conditions of this Agreement shall, at PHS’ sole option, be      considered by PHS      to be withdrawn from Licensee’s consideration      and the terms and conditions of this Agreement, and the Agreement itself      to be null and void, unless this Agreement is executed by the Licensee and a fully      executed original is received by PHS within sixty (60)      days from the date of PHS signature found at      the Signature Page. |
|--|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| For      PHS:                                                                                                                                                                                                                          |   |       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------|
|                                                                                                                                                                                                                              |   |       |    |
| Richard      U. Rodriguez.      M.B.A.             Date                                                                                                               |   | Date       |
| Director,      Division of Technology Development and Transfer                                                                                                                                                                         |   |       |
| Office      of Technology Transfer                                                                                                                                                                                                     |   |       |
| National      Institutes of Health                                                                                                                                                                                                     |   |       |
|                                                                                                                                                                                                                                   |   |       |
| Mailing      Address for Agreement      notices:                                                                                                                                                                                       |   |       |
|                                                                                                                                                                                                                                   |   |       |
| Chief,      Monitoring & Enforcement Branch, DTDT                                                                                                                                                                                  |   |       |
| Office      of Technology Transfer                                                                                                                                                                                                     |   |       |
| National      Institutes of Health                                                                                                                                                                                                     |   |       |
| 6011      Executive Boulevard, Suite 325                                                                                                                                                                                               |   |       |
| Rockville,      Maryland  20852-3804 U.S.A.                                                                                                                                                                                  |   |       |
|                                                                                                                                                                                                                                   |   |       |
| For      Licensee (Upon,      information and belief, the undersigned expressly certifies or affirms      that the contents of any statements of Licensee made or      referred to in this document are truthful and accurate.):  |
| by:                                                                                                                                                                                                                                    |   |       |
|                                                                                                                                                                                                                              |   |       |   |
| Signature      of Authorized Official                                                                                                                                                                                                  |   | Date  |
|                                                                                                                                                                                                                                   |   |       |
|                                                                                                                                                                                                                              |   |       |
| John      S. Kovach                                                                                                                                                                                                                    |   |       |
| Printed      Name                                                                                                                                                                                                                      |   |       |
|                                                                                                                                                                                                                                   |   |       |
|                                                                                                                                                                                                                              |   |       |
| Chief      Executive Officer                                                                                                                                                                                                           |   |       |
| Title                                                                                                                                                                                                                                  |   |       |

----

| I.          Official and Mailing Address for Agreement      notices:                                                                                                                                                                                                                                                                                                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
| John S.      Kovach                                                                                                                                                                                                                                      |   |
| Name                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
| Chief      Executive      Officer                                                                                                                                                                                               |   |
| Title                                                                                                                                                                                                                                                                                                                                                                                                                                                  |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
| Mailing      Address                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
| Lixte      Biotechnology, Inc.                                                                                                                                                                                                                                                                                                                                                                                                                         |   |
| 248      Route 25A #2                                                                                                                                                                                                                                                                                                                                                                                                                                  |   |
| East      Setauket, NY 11733                                                                                                                                                                                                                                                                                                                                                                                                                           |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
| Email      Address:                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
| Phone:       631-942-7959                                                                                                                                                                                                                                                                                                                                                                                           |   |
| Fax:           631-982-5050                                                                                                                                                                                                                                                                                                                                                                     |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
| II.    Official      and Mailing Address for Financial notices (Licensee’s contact      person for royalty payments)                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| John S.      Kovach                                                                                                                                                                                                                                      |   |
| Name                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
| Chief      Executive      Officer                                                                                                                                                                                               |   |
| Title                                                                                                                                                                                                                                                                                                                                                                                                                                                  |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
| Mailing      Address:                                                                                                                                                                                                                                                                                                                                                                                                                                  |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
| Lixte      Biotechnology, Inc.                                                                                                                                                                                                                                                                                                                                                                                                                         |   |
| 248      Route 25A #2                                                                                                                                                                                                                                                                                                                                                                                                                                  |   |
| East      Setauket, NY 11733                                                                                                                                                                                                                                                                                                                                                                                                                           |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
| Email      Address:                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
| Phone:            631-942-7959                                                                                                                                                                                                                                                                                                                                                                                           |   |
| Fax:           631-982-5050                                                                                                                                                                                                                                                                                                                                                                     |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |
| Any      false or misleading statements made, presented, or submitted to the Government, including      any relevant omissions, under this Agreement and during the      course of negotiation of this Agreement are subject to      all applicable civil and criminal statutes including Federal statutes 31      U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal      liability including fine(s) orimprisonment). |

----

| I. | U.S.      Provisional Patent Application No. 60/771,163, filed February 6, 2006,      entitled “Use of Phosphatases To Treat Glioblastomas” (HHS Ref. No.      E-123-2006/0-US-01); |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| II. | U.S.      Provisional Patent Application No. 60/797,201, filed May 2, 2006, entitled      “Use of Phosphatases To Treat Glioblastomas” (HHS Ref. No.      E-123-2006/1-US-01) |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| III. | U.S.      Patent Application Serial No. 11/703,401, filed February 6, 2007, entitled      “Use of Phosphatases To Treat Glioblastomas” (HHS Ref. No.      E-123-2006/0-US-03) |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| IV. | PCT      International Application No. PCT/US2007/003095, filed February 6, 2007      entitled “Use of Phosphatases To Treat Glioblastomas” (HHS Ref. No.      E-123-2006/0-PCT-02) |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| V. | U.S.      Provisional Patent Application No. 60/963,307, filed August 3, 2007      entitled “Use of Phosphatases To Treat Neuroblastomas and      Medulloblastomas” (HHS Ref. No.      E-123-2006/2-US-01) |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| VI. | U.S.      Provisional Patent Application No. 60/063,970, filed February 6, 2008      entitled “Use of Phosphatases To Treat Neuroblastomas and      Medulloblastomas”. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| VII. | U.S.      Application in preparation corresponding to Cooper and Dunham Referene No.      4101/79251. |
|------|-------------------------------------------------------------------------------------------------------|

----

| I. | Licensed Fields of      Use: |
|----|------------------------------|

|   | (a) | Treatment      of Glioblastomas and other Central Nervous System (CNS)    tumors |
|--------|-----|----------------------------------------------------------------------------------|

| II. | Licensed      Territory: |
|-----|--------------------------|

|   | (a) | Worldwide |
|--------|-----|-----------|

----

| I. | Licensee agrees to pay      to PHS a      noncreditable, nonrefundable license issue royalty in the amount of Twenty      Five Thousand dollars ($25,000) within sixty (60) days from the effective      date of this Agreement. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| II. | Licensee agrees to pay      PHS a      nonrefundable minimum annual royalty in the amount of Thirty Thousand      ($30,000) on January 1 of each calendar year following the year during      which the March 22, 2006 CRADA agreement, as appended, between the parties      is terminated and may be credited against any earned royalties due for      sales made in that year. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| III. | Licensee agrees to pay      PHS earned      royalties of Four and one-half percent (4.5%) on Net Sales by or on      behalf of Licensee      and its sublicensees. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| IV. | Licensee agrees to pay      PHSBenchmark royalties      within thirty (30) days of achieving each Benchmark: |
|-----|--------------------------------------------------------------------------------------------------------------|

|   | (a) | Fifty      Thousand dollars ($50,000) upon starting Phase I Clinical      Trials; |
|--------|-----|-----------------------------------------------------------------------------------|

|   | (b) | One      Hundred Thousand dollars ($100,000) upon starting Phase II Clinical      Trials; |
|--------|-----|-------------------------------------------------------------------------------------------|

|   | (c) | Two      Hundred Thousand dollars ($200,000) upon starting Phase III Clinical      Trials; |
|--------|-----|--------------------------------------------------------------------------------------------|

|   | (d) | Three      Hundred Thousand dollars ($300,000) upon filing an IND submission;      and |
|--------|-----|----------------------------------------------------------------------------------------|

|   | (e) | Six      Hundred Twenty Five Thousand dollars ($625,000) upon the First Commercial      Sale |
|--------|-----|----------------------------------------------------------------------------------------------|

| V. | Licensee agrees to pay      PHS additional      sublicensing royalties of fifteen percent (15%) on the fair market value      of any consideration received for granting each sublicense within sixty      (60) days of the execution of eachsublicense. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| I. | Initiation      of Phase I Clinical Trials – Est. Second Quarter,  2010 |
|----|-------------------------------------------------------------------------------|

| II. | Initiation      of Phase II Clinical Trials – Est. Second Quarter,  2011 |
|-----|--------------------------------------------------------------------------------|

| III. | Initiation      of Phase III Clinical Trials – Est. Third Quarter,  2012 |
|------|--------------------------------------------------------------------------------|

| IV. | Filing      of an IND Submission – Est. Fourth Quarter,2009 |
|-----|-------------------------------------------------------------------|

| V. | First      Commercial Sale Expected Timeline – Est. First Quarter,    2015 |
|----|----------------------------------------------------------------------------------|

----

----

|   | · | OTT      license reference number(L-XXX-200X/0) |
|--------|--------|-------------------------------------------------|

|   | · | Reporting      period |
|--------|--------|-----------------------|

|   | · | Catalog      number and units sold of each Licensed Product (domestic and      foreign) |
|--------|--------|-----------------------------------------------------------------------------------------|

|   | · | Gross      Sales per catalog number percountry |
|--------|--------|------------------------------------------------|

|   | · | Total      Gross Sales |
|--------|--------|------------------------|

|   | · | Itemized      deductions from Gross Sales |
|--------|--------|-------------------------------------------|

|   | · | Total      Net Sales |
|--------|--------|----------------------|

|   | · | Earned      Royalty Rate and associatedcalculations |
|--------|--------|-----------------------------------------------------|

|   | · | Gross      Earned Royalty |
|--------|--------|---------------------------|

|   | · | Adjustments      for Minimum Annual Royalty (MAR) and other creditable payments      made |
|--------|--------|-------------------------------------------------------------------------------------------|

|   | · | Net      Earned Royalty due |
|--------|--------|-----------------------------|

| Catalog Number |   | Product Name |   | Country |   | Units Sold |                          |   | Gross Sales (US$) |   |
|----------------|--------|--------------|--------|---------|--------|------------|-------------------------------|--------|-------------------|--------|
| 1              |   |         | A      |    | US     |       |                          | 250    |              |   |   | 62,500 |   |
| 1              |   |         | A      |    | UK     |       |                          | 32     |              |   |   | 16,500 |   |
| 1              |   |         | A      |    | France |       |                          | 25     |              |   |   | 15,625 |   |
| 2              |   |         | B      |    | US     |       |                          | 0      |              |   |   | 0 |   |
| 3              |   |         | C      |    | US     |       |                          | 57     |              |   |   | 57,125 |   |
| 4              |   |         | D      |    | US     |       |                          | 12     |              |   |   | 1,500 |   |
|           |   |         |   |    |   |       |                          |   |              |   |   |   |   |
|           |   |         |   |    |   |       | Total      Gross Sales        |   |              |   | 153,250 |   |
|           |   |         |   |    |   |       | Less      Deductions:         |   |              |   |   |   |
|           |   |         |   |    |   |       | Freight                       |   |              |   | 3,000 |   |
|           |   |         |   |    |   |       | Returns                       |   |              |   | 7,000 |   |
|           |   |         |   |    |   |       | Total      Net Sales          |   |              |   | 143,250 |   |
|           |   |         |   |    |   |       | Royalty      Rate             |   |              |   | 8 | % |
|           |   |         |   |    |   |       | Royalty      Due              |   |              |   | 11,460 |   |
|           |   |         |   |    |   |       | Less      Creditable Payments |   |              |   | 10,000 |   |
|           |   |         |   |    |   |       | Net      Royalty Due          |   |              |   | 1,460 |   |

----

----